Skip to main content

Methylene Blue

Source index · review incomplete

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated July 17, 2026; this date does not indicate completed review.

Mitochondrial & Energy982 cited mentions
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Methylene Blue; the papers are listed at the end. Research summary, not a recommendation.

What it is

Methylene blue (methylthioninium chloride) is a small synthetic dye, not a peptide. It was first made in 1876 as a textile dye, became one of the first synthetic drugs when it was used against malaria in the 1890s, and is still used as a tissue stain in surgery and the lab. An injectable pharmaceutical form (ProvayBlue) was approved by the FDA in 2016 as the antidote for acquired methemoglobinemia, a condition in which the blood cannot carry oxygen properly. Its use for energy, memory or ageing is off-label and rests on small human studies and animal work.

How it works

Methylene blue flips easily between a blue oxidized form and a colourless reduced form, so it can accept and hand on electrons. In methemoglobinemia it uses this to convert damaged haemoglobin (methemoglobin, which cannot carry oxygen) back to normal haemoglobin. In cells, the same electron-shuttling lets it pass electrons directly into the mitochondrial electron transport chain (the energy-producing chain inside mitochondria) at cytochrome c, which in lab and animal studies kept energy production going when parts of the chain were damaged and reduced harmful oxidant leaks. It is also a strong inhibitor of monoamine oxidase A, the enzyme that breaks down serotonin, which explains both its antidepressant-like effects in studies and its serious interaction with serotonin-raising drugs.

What it has been studied for

  • Acquired methemoglobinemia (FDA-approved antidote)
  • Mitochondrial support and neuroprotection (reviews of animal and lab studies)
  • Memory and attention in healthy adults (small randomized brain-imaging study)
  • Residual depression and anxiety in bipolar disorder (randomized crossover trial)
  • Alzheimer's disease, through its derivative LMTM (phase 3 randomized trial, negative primary result)
  • Cellular ageing (lab studies in human cells)

Strength of the evidence

Approved drugMethylene blue injection is FDA-approved for acquired methemoglobinemia; its cognitive, mood and anti-ageing uses rest on small randomized human studies and lab work, and a large Alzheimer's trial of a derivative was negative.

What the literature reports on safety

Because it blocks monoamine oxidase A, methylene blue taken with SSRIs, SNRIs or other serotonin-raising drugs has caused serotonin syndrome, a potentially fatal reaction, and the FDA issued a safety communication on this interaction in 2011. The approved label also warns against use in people with G6PD deficiency (it can cause destruction of red blood cells) and notes blue-green urine and skin discolouration and interference with pulse-oximeter readings. Industrial, aquarium or dye-grade methylene blue is not made to pharmaceutical purity standards.

Key papers

  1. From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue (opens in a new tab)

    Review · Tucker D, Lu Y, et al. · Molecular Neurobiology (2018) · PMID 28840449

    Reviewed how methylene blue shuttles electrons in mitochondria and the animal evidence for protection in stroke, brain injury and neurodegeneration.

  2. Methylene Blue: An Antidote for Methemoglobinemia and Beyond (opens in a new tab)

    Review · Pushparajah Mak RS, Liebelt EL · Pediatric Emergency Care (2021) · PMID 34463662

    Described how methylene blue reverses methemoglobinemia, its other emergency uses, and its key risks including G6PD deficiency and serotonin toxicity.

  3. The role of methylene blue in serotonin syndrome: a systematic review (opens in a new tab)

    Review · Ng BK, Cameron AJ · Psychosomatics (2010) · PMID 20484716

    Collected case reports and reviews showing that methylene blue combined with serotonin reuptake inhibitors caused serious serotonin syndrome.

  4. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain (opens in a new tab)

    Randomized trial · Rodriguez P, Zhou W, et al. · Radiology (2016) · PMID 27351678

    In a small placebo-controlled study of healthy adults, a low oral dose increased brain activity during attention and memory tasks and modestly improved memory retrieval.

  5. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study (opens in a new tab)

    Randomized trial · Alda M, McKinnon M, et al. · British Journal of Psychiatry (2017) · PMID 27284082

    Added to standard treatment, the active dose improved residual depression and anxiety compared with a very low comparison dose, without a significant effect on cognition.

  6. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial (opens in a new tab)

    Randomized trial · Gauthier S, Feldman HH, et al. · Lancet (2016) · PMID 27863809

    A large trial of LMTM, a stabilized form of methylene blue, did not show benefit as an add-on treatment for mild to moderate Alzheimer's disease.

  7. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways (opens in a new tab)

    Lab (in vitro) · Atamna H, Nguyen A, et al. · FASEB Journal (2008) · PMID 17928358

    In cultured human lung cells, very low concentrations increased mitochondrial complex IV activity and oxygen use and extended the number of divisions before the cells aged.

Sources checked: PubMed (E-utilities esummary and abstracts on every PMID), FDA label content as summarized in the cited reviews, written 2026-11-06.

Hunter Williams

→ profile

Protocol systematizer

Sources: compound titles first, then mentions

Dr Trevor Bachmeyer

→ profile

Acute vs chronic specialist

Sources: compound titles first, then mentions
7 earlier videos were removed from YouTube; titles kept for the record

Ask the Methylene Blue Librarian

Answers are generated from captured sources and may omit context or contain errors. Check the supporting passages.

What have the teachers said about Methylene Blue? Ask what it is, what they say it does, or where they discuss it. Questions about doses or personal use: ask your own clinician.

AI chat. To generate a reply, your question and recent chat history may be processed by Cloudflare Workers AI, Groq, Google Gemini or OpenRouter, depending on availability. Keep personal health details out of the chat and check the cited sources. Research use only; not medical advice.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Methylene Blue — Hunter, Taylor, Bachmeyer | Reset Biology